Skip to content

Switching to Very Low Nicotine Content Cigarettes vs Reducing Cigarettes Per Day

A Randomized Trial to Compare Switching to Very Low Nicotine Content Cigarettes vs Reducing Cigarettes Per Day

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03060083
Enrollment
74
Registered
2017-02-23
Start date
2017-02-08
Completion date
2018-01-10
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Use Disorder

Brief summary

The FDA recently gained the authority to regulate the nicotine content of cigarettes. Prior research suggests that smokers who switch to very low nicotine content (VLNC) cigarettes experience reduced addiction to nicotine and are more likely to quit smoking. Currently, the most common method for smokers to reduce their nicotine intake is to reduce their number of cigarettes per day (CPD). No research has compared reducing smokers' nicotine intake by switching to VLNC cigarettes vs by reducing CPD with regard to decreasing dependence or quitting; thus the investigators will examine the two strategies by randomizing smokers to 1) switch to VLNC cigarettes or 2) reduce CPD. In addition, all smokers will use the nicotine patch to help them reduce their nicotine intake.

Detailed description

Primary: 1. Determine the relative feasibility of switching to VLNC cigarettes vs reducing CPD when all participants are aided by nicotine replacement therapy (NRT). 2. Determine whether switching to VLNC cigarettes or reducing CPD more effectively reduces nicotine dependence when all participants are aided by NRT. Secondary: 3. Determine whether switching to VLNC cigarettes vs reducing CPD increases quit attempts and 7-day point-prevalence abstinence more when all participants are aided by NRT. 4. Determine the relative effectiveness of switching to VLNC cigarettes and reducing CPD when all participants are aided by NRT with comparisons of a) craving, b) withdrawal, c) perceived harm from smoking and d) participants' enjoyment from smoking. 5. Determine whether switching to VLNC cigarettes or reducing CPD increases use of e-cigarettes or other non-combustible nicotine products more. Rationale for Proposed Study: A policy to reduce the nicotine content of cigarettes could be useful for the majority of smokers who are not ready to quit. Specifically, the FDA recently gained the authority to regulate cigarettes' nicotine content and switching to very low nicotine content (VLNC) cigarettes has been proposed as a future regulatory policy to give smokers the option to decrease nicotine intake from cigarettes in order to decrease nicotine dependence and quit smoking. A review of clinical trials suggest that switching to VLNC cigarettes with and without nicotine replacement therapy (NRT) reduces dependence, carcinogens, and carbon monoxide and increases quitting; however, its long-term effects are unclear. Nicotine dependence is determined by nicotine intake (i.e., yield) as well as non-nicotine reinforcers conditioned by the repetitive act of smoking (i.e., multiple cigarettes per day). Presently, reducing cigarettes per day (CPD) is the most common strategy to reduce nicotine intake and appears to be an effective method of reducing dependence. However, a regulatory policy that introduces VLNC cigarettes will provide smokers with the opportunity to reduce nicotine intake without changing the frequency of their smoking behavior (i.e., CPD). Thus, reducing nicotine by switching to VLNC cigarettes may affect conditioned reinforcers and dependence differently than reducing nicotine intake via reducing CPD. The investigators know of no research that has compared the regulatory policy of reducing nicotine intake via VLNC cigarettes vs the common method of reducing nicotine intake via reducing CPD. This comparison will provide important information regarding the components involved in changing nicotine dependence and the potential effects of a policy that regulates the nicotine content of cigarettes. NRT appears to increase the feasibility and effectiveness of switching to VLNC cigarettes as well as reducing full nicotine CPD. In both scenarios, NRT facilitates a net reduction in nicotine. Further, NRT is currently available to smokers who reduce CPD, will be available to smokers if cigarettes' nicotine levels are reduced by the FDA, and is likely to be used as an aid for both. The present study will compare participants who switch to VLNC cigarettes vs participants who reduce CPD when all participants receive NRT patch. Specifically this comparison will examine differences in feasibility and effectiveness of reducing nicotine dependence. Study Design: Consenting participants will be randomly assigned to 1) switch to VLNC cigarettes with NRT or 2) reduce full nicotine CPD with NRT during the 5-week study period. All participants will complete baseline measures and receive full nicotine or VLNC study cigarettes as well as weekly supplies of 21-mg nicotine patches with instructions to replace their old patch with a new patch each morning. During their first study visit, the investigators will provide all participants with a one-week supply of full nicotine study cigarettes (16.5 ± 0.17 mg/g) that totals 150% of their normal number of CPD in order to establish a baseline CPD with novel study cigarettes that are being provided free of charge. The 16.5 mg/g nicotine content NIDA research cigarette is estimated to have a nicotine yield (0.8 mg) similar to many commercial cigarettes. Participants will be instructed to smoke only study cigarettes, but to smoke as usual during the first week of the study. All study cigarettes are for investigational purposes only and are not available or intended for commercial use. Switching to VLNC cigarettes Participants who are randomized to switch to VLNC cigarettes will receive a supply of 100% of their baseline number of CPD during study visits (determined during week 1) throughout weeks 2 to 5 and instructed to smoke as usual (e.g., not to attempt to reduce CPD). They will receive study cigarettes with progressively lower nicotine content (mg/g tobacco) beginning with 11.26 ± 0.11 mg/g during week 2, 5.54 ± 0.27 mg/g during week 3, 2.54 ± 0.05 mg/g during week 4, and 0.44 ± 0.01 mg/g during week 5. Participants will also receive a supply of NRT patches with instructions to wear one patch per day every day throughout weeks 2 through 5. This schedule was selected based on available VLNC cigarettes and findings that indicate that a gradual transition to cigarettes with a nicotine content of approximately 1 mg/g or less with the NRT patch is safe, effective and feasible. The investigators will estimate NRT use and compliance with VLNC study cigarettes with daily and weekly self report. Reducing CPD The investigators will provide participants who are randomized to reduce CPD with full nicotine study cigarettes (16.5 ± 0.17 mg/g) during each study visit throughout the 5-week study period and instruct them to only smoke cigarettes provided by the study. After establishing a baseline CPD during week 1, participants will receive progressively fewer cigarettes beginning with 70% of their baseline CPD during week 2, 35% during week 3, 15% during week 4, and 3% during week 5. Participants will receive a minimum of 1 CPD during week 5. Participants will also receive a supply of NRT patches with instructions to wear one patch per day every day throughout weeks 2 through 5. This schedule was selected to match the percent reduction in nicotine content of cigarettes for smokers randomized to switch to VLNC cigarettes. Further, this schedule of NRT aided reductions in CPD appears to be safe, feasible and effective. The investigators will estimate reductions in CPD, compliance with study cigarettes, and NRT use with daily and weekly self-report.

Interventions

OTHERVery low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT)

Participants will switch to very low nicotine content (VLNC) cigarettes with the aid of nicotine replacement therapy (NRT)

OTHERReduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)

Participants will reduce cigarettes per day (CPD) with the aid of nicotine replacement therapy (NRT)

Sponsors

University of Vermont
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Eligibility will be determined based on: * participants' age, * their cigarettes smoked per day, * their intention to quit, * their willingness to use medications, * prior use of tobacco and non-tobacco nicotine products, * prior use of stop-smoking services or medications, * DSM 5 criteria for Tobacco Use Disorder, * current use of opioid maintenance medications, * access to a telephone and the Internet, * proximity to the University of Vermont, * their bed time, * status as a US citizen, * comfort speaking, reading and writing in English, and * whether or not the participant is breast feeding, pregnant or has the potential to become pregnant or begin breastfeeding during the study period.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility as Indicated by Self-reported Adherence to Study Cigarettes.Assessed weekly during the 4 week reduction period after the baseline weekThe investigators will use non-adherence to nicotine reduction (i.e., self report of percent non-study cigarettes per day) as an indicator of feasibility.
Self Reported Dependence Using the Nicotine Dependence Syndrome Scale (NDSS)Assessed weekly during the 4 week reduction period after the baseline weekThe NDSS is a measure of dependence that does not rely on cigarettes per day as an indicator of dependence.

Secondary

MeasureTime frameDescription
Any Quit Attempt (QA)Participants were asked at the end of the reduction period whether they made a quit attempt at any point during the 4 week reduction period.The percent of participants in each condition who made one or more self-reported quit attempts to stop smoking for good during the study period, lasting any length of time (including attempts lasting less than 24 hours).
Number of Participants With Self Reported Seven Day Point Prevalence AbstinenceAssessed at the end of the 4 week reduction periodSelf reported seven day point prevalence abstinence.
Self-efficacy to Quit SmokingWeek 0 - Week 4Velicer's self-efficacy scale is a self-report measure of self-efficacy to quit smoking (1=least to 5=most).

Countries

United States

Participant flow

Participants by arm

ArmCount
Switch to VLNC Cigarettes
Participants will be instructed to use nicotine patches and gradually switch to very low nicotine content (VLNC) cigarettes throughout the study period. They will receive regular nicotine cigarettes (16.5 mg/g) during week 1, 11.26 mg/g cigarettes during week 2, 5.54 mg/g cigarettes during week 3, 2.54 mg/g cigarettes during week 4, and 0.44 mg/g cigarettes during week 5. Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT): Participants will switch to very low nicotine content (VLNC) cigarettes with the aid of nicotine replacement therapy (NRT)
36
Reduce CPD
Participants will be instructed to use nicotine patches and gradually reduce the number of regular nicotine content cigarettes that they smoke throughout the study period. They will receive regular nicotine content cigarettes (16.5 mg/g) throughout the study study period. After establishing a baseline CPD during week 1, participants will receive 70% of their baseline CPD during week 2, 35% during week 3, 15% during week 4, and 3% during week 5. Participants will receive a minimum of 1 CPD during week 5. Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT): Participants will reduce cigarettes per day (CPD) with the aid of nicotine replacement therapy (NRT)
32
Total68

Baseline characteristics

CharacteristicReduce CPDTotalSwitch to VLNC Cigarettes
Age, Continuous39.3 years
STANDARD_DEVIATION 13.6
38.8 years
STANDARD_DEVIATION 13.4
38.4 years
STANDARD_DEVIATION 13.4
Race/Ethnicity, Customized
Race/Ethnicity
American Indian or Alaska Native, non-Hispanic
0 Participants0 Participants0 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Asian, non-Hispanic
0 Participants0 Participants0 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Black, non-Hispanic
1 Participants2 Participants1 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Hispanic
0 Participants0 Participants0 Participants
Race/Ethnicity, Customized
Race/Ethnicity
More than one race
2 Participants5 Participants3 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Pacific Islander, non-Hispanic
0 Participants0 Participants0 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Prefer not to answer
0 Participants2 Participants2 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Some other race
1 Participants3 Participants2 Participants
Race/Ethnicity, Customized
Race/Ethnicity
White, non-Hispanic
28 Participants56 Participants28 Participants
Sex: Female, Male
Female
13 Participants27 Participants14 Participants
Sex: Female, Male
Male
19 Participants41 Participants22 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 360 / 32
other
Total, other adverse events
30 / 3625 / 32
serious
Total, serious adverse events
0 / 360 / 32

Outcome results

Primary

Feasibility as Indicated by Self-reported Adherence to Study Cigarettes.

The investigators will use non-adherence to nicotine reduction (i.e., self report of percent non-study cigarettes per day) as an indicator of feasibility.

Time frame: Assessed weekly during the 4 week reduction period after the baseline week

Population: Feasibility was assessed with percent non-study cigarettes. Greater percent non-study cigarettes per day indicates less feasibility. See the full paper for more detailed outcomes: https://doi.org/10.1111/add.14666

ArmMeasureGroupValue (MEAN)Dispersion
Switch to VLNC CigarettesFeasibility as Indicated by Self-reported Adherence to Study Cigarettes.Week 110.4 Percent non-study cigarettes per dayStandard Error 0.03
Switch to VLNC CigarettesFeasibility as Indicated by Self-reported Adherence to Study Cigarettes.Week 314.1 Percent non-study cigarettes per dayStandard Error 0.05
Switch to VLNC CigarettesFeasibility as Indicated by Self-reported Adherence to Study Cigarettes.Week 214.8 Percent non-study cigarettes per dayStandard Error 0.05
Switch to VLNC CigarettesFeasibility as Indicated by Self-reported Adherence to Study Cigarettes.Week 421.4 Percent non-study cigarettes per dayStandard Error 0.06
Switch to VLNC CigarettesFeasibility as Indicated by Self-reported Adherence to Study Cigarettes.Baseline (Week 0)7.1 Percent non-study cigarettes per dayStandard Error 0.03
Reduce CPDFeasibility as Indicated by Self-reported Adherence to Study Cigarettes.Week 472.3 Percent non-study cigarettes per dayStandard Error 0.06
Reduce CPDFeasibility as Indicated by Self-reported Adherence to Study Cigarettes.Baseline (Week 0)7.3 Percent non-study cigarettes per dayStandard Error 0.03
Reduce CPDFeasibility as Indicated by Self-reported Adherence to Study Cigarettes.Week 113.3 Percent non-study cigarettes per dayStandard Error 0.04
Reduce CPDFeasibility as Indicated by Self-reported Adherence to Study Cigarettes.Week 231.2 Percent non-study cigarettes per dayStandard Error 0.05
Reduce CPDFeasibility as Indicated by Self-reported Adherence to Study Cigarettes.Week 352.3 Percent non-study cigarettes per dayStandard Error 0.06
Primary

Self Reported Dependence Using the Nicotine Dependence Syndrome Scale (NDSS)

The NDSS is a measure of dependence that does not rely on cigarettes per day as an indicator of dependence.

Time frame: Assessed weekly during the 4 week reduction period after the baseline week

Population: The NDSS overall score is reported has a t-score (range= -3.9 to 2.3) with lower scores indicating lower nicotine dependence. Please see full paper for further results: https://doi.org/10.1111/add.14666

ArmMeasureGroupValue (MEAN)Dispersion
Switch to VLNC CigarettesSelf Reported Dependence Using the Nicotine Dependence Syndrome Scale (NDSS)Week 1-1.1 t-scoreStandard Error 0.15
Switch to VLNC CigarettesSelf Reported Dependence Using the Nicotine Dependence Syndrome Scale (NDSS)Week 3-1.4 t-scoreStandard Error 0.14
Switch to VLNC CigarettesSelf Reported Dependence Using the Nicotine Dependence Syndrome Scale (NDSS)Week 2-1.2 t-scoreStandard Error 0.17
Switch to VLNC CigarettesSelf Reported Dependence Using the Nicotine Dependence Syndrome Scale (NDSS)Week 4-1.7 t-scoreStandard Error 0.15
Switch to VLNC CigarettesSelf Reported Dependence Using the Nicotine Dependence Syndrome Scale (NDSS)Baseline (Week 0)-0.7 t-scoreStandard Error 0.17
Reduce CPDSelf Reported Dependence Using the Nicotine Dependence Syndrome Scale (NDSS)Week 4-1.3 t-scoreStandard Error 0.16
Reduce CPDSelf Reported Dependence Using the Nicotine Dependence Syndrome Scale (NDSS)Baseline (Week 0)-0.8 t-scoreStandard Error 0.18
Reduce CPDSelf Reported Dependence Using the Nicotine Dependence Syndrome Scale (NDSS)Week 1-1.0 t-scoreStandard Error 0.16
Reduce CPDSelf Reported Dependence Using the Nicotine Dependence Syndrome Scale (NDSS)Week 2-1.2 t-scoreStandard Error 0.18
Reduce CPDSelf Reported Dependence Using the Nicotine Dependence Syndrome Scale (NDSS)Week 3-1.4 t-scoreStandard Error 0.15
Secondary

Any Quit Attempt (QA)

The percent of participants in each condition who made one or more self-reported quit attempts to stop smoking for good during the study period, lasting any length of time (including attempts lasting less than 24 hours).

Time frame: Participants were asked at the end of the reduction period whether they made a quit attempt at any point during the 4 week reduction period.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Switch to VLNC CigarettesAny Quit Attempt (QA)6 Participants
Reduce CPDAny Quit Attempt (QA)13 Participants
Secondary

Number of Participants With Self Reported Seven Day Point Prevalence Abstinence

Self reported seven day point prevalence abstinence.

Time frame: Assessed at the end of the 4 week reduction period

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Switch to VLNC CigarettesNumber of Participants With Self Reported Seven Day Point Prevalence Abstinence0 Participants
Reduce CPDNumber of Participants With Self Reported Seven Day Point Prevalence Abstinence1 Participants
Secondary

Self-efficacy to Quit Smoking

Velicer's self-efficacy scale is a self-report measure of self-efficacy to quit smoking (1=least to 5=most).

Time frame: Week 0 - Week 4

ArmMeasureGroupValue (MEAN)Dispersion
Switch to VLNC CigarettesSelf-efficacy to Quit SmokingWeek 12.6 units on a scaleStandard Error 0.17
Switch to VLNC CigarettesSelf-efficacy to Quit SmokingWeek 33.1 units on a scaleStandard Error 0.17
Switch to VLNC CigarettesSelf-efficacy to Quit SmokingWeek 22.7 units on a scaleStandard Error 0.17
Switch to VLNC CigarettesSelf-efficacy to Quit SmokingWeek 43.4 units on a scaleStandard Error 0.18
Switch to VLNC CigarettesSelf-efficacy to Quit SmokingBaseline (Week 0)2.5 units on a scaleStandard Error 0.16
Reduce CPDSelf-efficacy to Quit SmokingWeek 42.6 units on a scaleStandard Error 0.19
Reduce CPDSelf-efficacy to Quit SmokingBaseline (Week 0)2.9 units on a scaleStandard Error 0.17
Reduce CPDSelf-efficacy to Quit SmokingWeek 12.7 units on a scaleStandard Error 0.18
Reduce CPDSelf-efficacy to Quit SmokingWeek 22.8 units on a scaleStandard Error 0.18
Reduce CPDSelf-efficacy to Quit SmokingWeek 32.8 units on a scaleStandard Error 0.19

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026